A5015700716- Autoimmune and Inflammatory Disorders Research
- Adolescent and Pediatric Healthcare
- Ocular Diseases and Behçet’s Syndrome
- Systemic Lupus Erythematosus Research
- Kawasaki Disease and Coronary Complications
- Inflammasome and immune disorders
- Osteomyelitis and Bone Disorders Research
- COVID-19 Clinical Research Studies
- Infectious Diseases and Tuberculosis
- Orthopedic Infections and Treatments
- Spondyloarthritis Studies and Treatments
- Acute Lymphoblastic Leukemia research
- Immunodeficiency and Autoimmune Disorders
- Immune Cell Function and Interaction
- Rheumatoid Arthritis Research and Therapies
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- Retinal and Optic Conditions
- Renal Diseases and Glomerulopathies
- Otitis Media and Relapsing Polychondritis
- Parvovirus B19 Infection Studies
- Childhood Cancer Survivors' Quality of Life
- Diabetes and associated disorders
- Coronary Artery Anomalies
- Mechanical Circulatory Support Devices
Bristol Royal Hospital for Children
2016-2025
University of Bristol
2016-2025
University Hospitals Bristol NHS Foundation Trust
2014-2024
University Hospitals Bristol and Weston NHS Foundation Trust
2020-2024
National Health Service
2013-2023
National Institute for Health Research
2013-2021
Oxford University Clinical Research Unit
2021
NIHR Clinical Research Network
2021
National Records of Scotland
2021
Intensive Care National Audit & Research Centre
2021
Objective To develop criteria for the classification of macrophage activation syndrome (MAS) in patients with systemic juvenile idiopathic arthritis (JIA). Methods A multistep process, based on a combination expert consensus and analysis real patient data, was conducted. panel 28 experts first asked to classify 428 profiles as having or not MAS, clinical laboratory features at time disease onset. The comprised 161 JIA–associated MAS 267 condition that could potentially be confused (active...
Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, is effective in the treatment of juvenile idiopathic arthritis (JIA). We tested efficacy adalimumab JIA-associated uveitis.In this multicenter, double-blind, randomized, placebo-controlled trial, we assessed and safety children adolescents 2 years age or older who had active uveitis. Patients were taking stable dose methotrexate randomly assigned 2:1 ratio to receive either (at 20 mg 40 mg, according body weight)...
To develop criteria for the classification of macrophage activation syndrome (MAS) in patients with systemic juvenile idiopathic arthritis (JIA). A multistep process, based on a combination expert consensus and analysis real patient data, was conducted. panel 28 experts first asked to classify 428 profiles as having or not MAS, clinical laboratory features at time disease onset. The comprised 161 JIA—associated MAS 267 condition that could potentially be confused (active JIA without evidence...
Abstract Objective Macrophage activation syndrome is characterized by an overwhelming inflammatory reaction driven excessive expansion of T cells and hemophagocytic macrophages. Levels soluble interleukin‐2 receptor α (sIL‐2Rα) CD163 (sCD163) may reflect the degree macrophages, respectively. This study was undertaken to assess value serum sIL‐2Rα sCD163 in diagnosing acute macrophage complicating systemic juvenile idiopathic arthritis (JIA). Methods Enzyme‐linked immunosorbent assay used...
Chronic recurrent multifocal osteomyelitis (CRMO) is a little known inflammatory bone disease occurring primarily in children and adolescents. Delays referral diagnosis may lead to prolonged courses of antibiotics with in-patient care, unnecessary radiation exposure from multiple plain radiographs or scans repeated surgery including biopsies. Children (aged < 18 years) diagnosed CRMO between January 2005 December 2012, reviewed at Bristol Royal Hospital for were included all available data...
An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in era biologics.The availability biologic agents human eye disease has altered practice patterns management uveitis. Current guidelines are insufficient assure optimal use noncorticosteroid systemic immunomodulatory agents.An international expert steering committee comprising 9 specialists (including both ophthalmologists and rheumatologists)...
Global randomised controlled trials of the anti-IL-6 receptor antibody tocilizumab in patients admitted to hospital with COVID-19 have shown conflicting results but potential decreases time discharge and burden on intensive care. Tocilizumab reduced progression mechanical ventilation death a trial population enriched for racial ethnic minorities. We aimed investigate whether treatment could prevent first multicentre done entirely lower-middle-income country.
Pediatric coronavirus disease-19 (COVID-19) infection is relatively mild when compared to adults, and children are reported have a better prognosis. Mortality in appears rare. Clinical features of COVID-19 include fever cough, but large proportion infected be asymptomatic may contribute transmission. It remains unclear why young adults less severely affected than older individuals, this might involve differences immune system function the elderly and/or expression/function cellular receptor...
In 2012, a European initiative called Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) was launched to optimise disseminate diagnostic management regimens children young adults with rheumatic diseases. Juvenile idiopathic arthritis (JIA) is the most common disease uveitis possibly its devastating extra-articular manifestation. Evidence-based guidelines are sparse mostly based on physicians' experience. Consequently, treatment practices differ widely, within between...
Objective. To evaluate the efficacy of mycophenolate mofetil (MMF) in treatment severe refractory juvenile localized scleroderma (JLS). Methods. A retrospective chart review was performed patients with JLS who had been treated MMF after failure a combination MTX and corticosteroids for at least 4 months, or whose concomitant extracutaneous manifestations. Outcome assessed through clinical examination thermography. Adverse events were recorded. Results. Ten (six females four males) enrolled...
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Children with JIA are at risk of inflammation uvea eye (uveitis). Overall, 20% to 25% paediatric uveitis associated JIA. Major factors for development oligoarticular pattern arthritis, an age onset less than seven years age, and antinuclear antibody positivity. In initial stages mild moderate asymptomatic. This has led current practice screening all children uveitis. Approximately 12% 38% patients develop...
To report on experience using the anti-interleukin 6 receptor antibody tocilizumab (TCZ) to treat severe and therapy-refractory uveitis associated with juvenile idiopathic arthritis (JIA).Retrospective data were gathered from patients JIA receiving TCZ treatment for uveitis. related (disease onset, activity, structural complications, topical systemic antiinflammatory treatment) evaluated at start of (baseline) every 3 months during therapy.A total 17 (14 women) active included (mean age 15.3...
Paediatric Multisystem Inflammatory Syndrome temporally associated with SARS-CoV-2 (PIMS-TS), first identified in April 2020, shares features of both Kawasaki disease (KD) and toxic shock syndrome (TSS). The surveillance describes the epidemiology clinical characteristics PIMS-TS United Kingdom Ireland. Public Health England initiated prospective national through British Surveillance Unit. Paediatricians were contacted monthly to report PIMS-TS, KD TSS cases electronically complete a...
Objectives To evaluate the long-term efficacy and safety of canakinumab in patients with active systemic juvenile idiopathic arthritis (JIA). Methods Patients (2–19 years) entered two phase III studies continued extension (LTE) study. Efficacy assessments were performed every 3 months, including adapted JIA American College Rheumatology (aJIA-ACR) criteria, Juvenile Arthritis Disease Activity Score (JADAS) ACR clinical remission on medication criteria (CR ). analyses are reported as per...